HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Centerhave discovered an immune regulator that appears to dictate glioblastoma (GBM) progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation. Findings from the preclinical study led by Shulin Li, Ph.D., professor of Pediatrics, and Amy Heimberger, M.D., professor of Neurosurgery, were published in the Jan. 25 online issue of Nature Communications. “Classical wisdom is that brain tumor progression is linked to oncogene activation and tumor suppressor gene inactivation; however genetic […]
